| |
| |
|
| Insider
Information: |
Valle Franco |
| Relationship: |
|
| City: |
San Carlos |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
25,673 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$317,228 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
25,673 |
|
|
| Total
Value |
$317,228 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
2
|
8
|
|
Stock
price went up :
|
2
|
6
|
| Stock
price went down : |
0
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
2.0
|
3.0
|
| Percentage
Gain/Loss : |
 84.6%
|
534.3%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Iovance Biotherapeutics Inc |
IOVA |
Officer |
2016-08-22 |
130 |
|
0 |
Premium* |
|
|
Eidos Therapeutics, Inc. |
EIDX |
Senior Vice President,... |
2021-01-12 |
0 |
2020-03-02 |
0 |
Premium* |
|
|
Biomea Fusion, Inc. |
BMEA |
|
2023-11-30 |
25,543 |
2022-01-14 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
24 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| BMEA |
Biomea Fusion, Inc. |
Chief Financial Officer |
• – – |
2023-11-30 |
4 |
A |
$3.78 |
$5,087 |
D/D |
1,345 |
25,543 |
0 |
- |
|
| BMEA |
Biomea Fusion, Inc. |
Chief Financial Officer |
• – – |
2023-05-31 |
4 |
A |
$3.78 |
$16,163 |
D/D |
4,273 |
24,198 |
0 |
- |
|
| BMEA |
Biomea Fusion, Inc. |
Chief Financial Officer |
• – – |
2022-11-30 |
4 |
A |
$3.78 |
$9,524 |
D/D |
2,518 |
19,925 |
0 |
- |
|
| BMEA |
Biomea Fusion, Inc. |
Chief Financial Officer |
• – – |
2022-11-11 |
4 |
B |
$7.63 |
$31,286 |
D/D |
4,100 |
17,407 |
2.74 |
% |
|
| BMEA |
Biomea Fusion, Inc. |
Chief Financial Officer |
• – – |
2022-05-31 |
4 |
A |
$4.67 |
$15,432 |
D/D |
3,307 |
13,307 |
0 |
- |
|
| BMEA |
Biomea Fusion, Inc. |
Chief Financial Officer |
• – – |
2022-01-14 |
4 |
B |
$8.68 |
$86,767 |
D/D |
10,000 |
10,000 |
2.74 |
% |
|
| EIDX |
Eidos Therapeutics, Inc. |
Senior Vice President, Finance |
• – – |
2021-01-12 |
4 |
OE |
$7.24 |
$12,648 |
D/D |
1,747 |
1,747 |
0 |
- |
|
| EIDX |
Eidos Therapeutics, Inc. |
Senior Vice President, Finance |
• – – |
2021-01-12 |
4 |
S |
$125.45 |
$219,152 |
D/D |
(1,747) |
0 |
0 |
% |
|
| EIDX |
Eidos Therapeutics, Inc. |
Senior Vice President, Finance |
• – – |
2021-01-11 |
4 |
S |
$125.61 |
$188,408 |
D/D |
(1,500) |
0 |
0 |
% |
|
| EIDX |
Eidos Therapeutics, Inc. |
Senior Vice President, Finance |
• – – |
2021-01-11 |
4 |
OE |
$7.24 |
$10,860 |
D/D |
1,500 |
1,500 |
0 |
- |
|
| EIDX |
Eidos Therapeutics, Inc. |
Senior Vice President, Finance |
• – – |
2020-11-09 |
4 |
S |
$74.93 |
$121,609 |
D/D |
(1,623) |
0 |
0 |
% |
|
| EIDX |
Eidos Therapeutics, Inc. |
Senior Vice President, Finance |
• – – |
2020-11-09 |
4 |
OE |
$7.24 |
$11,751 |
D/D |
1,623 |
1,623 |
0 |
- |
|
| EIDX |
Eidos Therapeutics, Inc. |
Senior Vice President, Finance |
• – – |
2020-10-08 |
4 |
S |
$74.85 |
$389,151 |
D/D |
(5,199) |
0 |
0 |
% |
|
| EIDX |
Eidos Therapeutics, Inc. |
Senior Vice President, Finance |
• – – |
2020-10-08 |
4 |
OE |
$7.24 |
$37,641 |
D/D |
5,199 |
5,199 |
0 |
- |
|
| EIDX |
Eidos Therapeutics, Inc. |
Senior Vice President, Finance |
• – – |
2020-10-07 |
4 |
S |
$75.08 |
$408,748 |
D/D |
(5,444) |
0 |
0 |
% |
|
| EIDX |
Eidos Therapeutics, Inc. |
Senior Vice President, Finance |
• – – |
2020-10-07 |
4 |
OE |
$7.24 |
$36,200 |
D/D |
5,000 |
5,444 |
0 |
- |
|
| EIDX |
Eidos Therapeutics, Inc. |
Senior Vice President, Finance |
• – – |
2020-05-31 |
4 |
A |
$41.57 |
$18,459 |
D/D |
444 |
444 |
0 |
- |
|
| EIDX |
Eidos Therapeutics, Inc. |
Senior Vice President, Finance |
• – – |
2020-04-20 |
4 |
OE |
$7.24 |
$14,480 |
D/D |
2,000 |
2,000 |
0 |
- |
|
| EIDX |
Eidos Therapeutics, Inc. |
Senior Vice President, Finance |
• – – |
2020-04-20 |
4 |
S |
$49.79 |
$99,580 |
D/D |
(2,000) |
0 |
0 |
% |
|
| EIDX |
Eidos Therapeutics, Inc. |
Senior Vice President, Finance |
• – – |
2020-03-26 |
4 |
S |
$47.87 |
$241,310 |
D/D |
(5,000) |
0 |
0 |
% |
|
| EIDX |
Eidos Therapeutics, Inc. |
Senior Vice President, Finance |
• – – |
2020-03-26 |
4 |
OE |
$7.24 |
$36,200 |
D/D |
5,000 |
5,000 |
0 |
- |
|
| EIDX |
Eidos Therapeutics, Inc. |
Senior Vice President, Finance |
• – – |
2020-03-02 |
4 |
S |
$51.96 |
$156,980 |
D/D |
(3,000) |
0 |
0 |
% |
|
| EIDX |
Eidos Therapeutics, Inc. |
Senior Vice President, Finance |
• – – |
2020-03-02 |
4 |
OE |
$7.24 |
$21,720 |
D/D |
3,000 |
3,000 |
0 |
- |
|
| IOVA |
Iovance Biotherapeutics I... |
Principal Accounting OfficerOf |
• – – |
2016-08-22 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
130 |
|
- |
|
24 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
